Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
May 7, 2026
Earnings Call Speaker Segments
Vivian Wu
executiveAppreciate that, Crystal, and good afternoon to all of you. We're glad you could be with us today. During this call, you'll be hearing from Howard Robin, who serves as our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Sandra Gardiner, our Chief Financial Officer. Dr. Mary Tagliaferri, our Chief Medical Officer, will also be on hand for the Q&A. Before getting started, I want to remind everyone that forward-looking statements about our business will be made, including ones concerning the therapy potential and development plans for rezpegaldesleukin, the timing and expectations for clinical data presentations, regulatory interactions, and other statements about the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict and many of which lie outside our control; for a discussion of these risks and uncertainties, please refer to our filings with the SEC, including our most recent Form 10-K and subsequent filings; we undertake no obligation to update these forward-looking statements except as required by law. A live webcast and replay of this call will be available on the Investor Relations section of our website at nektar.com. With that, I'll hand the call over to Howard.
Howard Robin
executiveThanks, Vivian, and good afternoon to all of you. At the company, we take enormous pride in how far we've come. What we've shared from our Phase IIb trials in atopic dermatitis and alopecia areata across the past 12 months shows that REZPEG may deliver clinically meaningful results across 2 separate autoimmune and inflammatory disease settings. Equally important, the data sets we released in February and April of this year underscore REZPEG's potential to bring patients even greater benefit as time goes on. Back in February of this year, we presented the long-term monthly and quarterly dosing findings from the 36-week maintenance phase of REZOLVE-AD in atopic dermatitis patients. Those results revealed substantial durability along with efficacy that deepened further, and they solidified a highly differentiated profile for REZPEG as a novel regulatory T cell mechanism. With these results behind us, we're acting fast to launch the ZENITH-AD Phase III program in moderate to severe atopic dermatitis patients by July of this year. Our discussions with regulatory authorities regarding the Phase III program are now finished, and later on this call JZ will walk through the program's components; we anticipate the first Phase III data in mid-2028, which will underpin our aim of filing a BLA in 2029. Novel mechanisms are still needed in atopic dermatitis beyond what the current treatment landscape offers; here in the U.S., more than 15 million individuals suffer from moderate to severe atopic dermatitis, yet under 10% receive biologic treatments for this chronic skin disorder, and many of those patients don't respond well to agents already on the market. Among patients taking currently approved agents, including Dupixent and other IL-13 based mechanisms, roughly 50% either fail to respond or see their treatment effect fade with time. That creates a major opening for REZPEG to step into the treatment paradigm in a lead position as a novel immune modulating mechanism capable of giving both naive and experienced patients a differentiated efficacy and safety profile plus monthly or quarterly long-term maintenance dosing. Now to alopecia areata; in April, we reported positive 52-week top line results from the blinded treatment extension period of the Phase II REZOLVE-AA study. Those data likewise showed efficacy deepening and clinically meaningful improvement across a large number of SALT measurements with REZPEG dosed twice monthly. Our view is that REZPEG can now move forward as a compelling first-in-class biologic candidate capable of transforming the treatment paradigm for people living with this condition. Close to 6.7 million people in the U.S. live with alopecia areata, and the vast majority go untreated. Over 50% of dermatologists have hesitated to prescribe JAK inhibitors, the only approved systemic therapies, given box warnings and the difficulties of ongoing clinical monitoring. We recognize that an unmet need persists for an efficacious and safe biologic offering a better safety, efficacy and dosing profile. Drawing on what we've heard from key opinion leaders and our own market research, we see a substantial opening for REZPEG to secure frontline share within this indication. Our plan is to launch the Phase III program in alopecia areata during the early portion of 2027, which would add a second possible indication to Nektar's BLA submission for REZPEG. Over the coming 5 years, the combined worldwide markets for atopic dermatitis and alopecia areata should approach roughly $40 billion. In our view, adoption of novel mechanisms such as REZPEG could push that market to expand even more. We observed this dynamic when new mechanisms entered the psoriasis market across time — patients served increased tenfold across 15 years and today sustains 7 blockbuster products. That expansion came not just from drugs fighting over the same patients. Every fresh mechanism drew in new prescribing physicians who had not previously been treating with systemic therapies. Our sense is that atopic dermatitis and alopecia areata may sit at a comparable inflection point right now, and as a genuinely novel MOA, we think REZPEG is capable of transforming the treatment paradigm across both indications; furthermore, and importantly, we see potential for Treg biology and REZPEG to apply beyond atopic dermatitis and alopecia areata. Nektar today stands in a very strong financial position to back REZPEG's advancement. From year-end onward, we brought in about $783 million in net proceeds across 2 financings; the first quarter of 2026 closed with $731 million in cash, and that figure excludes our April financing, which contributes an additional $350 million to our balance sheet, taking total cash and investments as of today above $1 billion. Given this financial strength, we could move into Phase III for both indications with a cash runway extending into the third quarter of 2028, well beyond when we expect data readouts. I'll hand the call to JZ now so he can walk through our clinical programs in more detail. JZ?
Jonathan Zalevsky
executiveThanks, Howard. Hello, everyone, and good afternoon. Like Howard mentioned, throughout the last 12 months, the clinical results we've produced from REZOLVE-AD along with REZOLVE-AA have verified that our REZPEG strategy of stimulating regulatory T cells converts into a clinical profile that sets us apart: strong efficacy, a safety profile that's favorable, less frequent dosing, and responses that get deeper as time passes. Whereas other treatments inhibit one inflammatory pathway downstream, REZPEG works upstream, bringing back the basic immune equilibrium that gets thrown off in autoimmune and inflammatory conditions. Back in June, we shared the 16-week induction phase from REZOLVE-AD, where REZPEG showed efficacy with a fast onset on the key measures of EASI-75 and itch. On the primary endpoint of mean percent change in EASI score, REZPEG additionally hit statistical significance, and at week 16, the high dose reached statistical significance across all key secondary endpoints. From the 24-week crossover data on patients first randomized to placebo who then crossed over to high dose REZPEG given every 2 weeks, we observed responses deepening further without any indication of a plateau. Those results reinforced our choice to move a 24-week induction period into Phase III. During the 36-week maintenance phase, when patients went on to receive REZPEG at less frequent monthly and quarterly intervals, we kept seeing the induction responses hold up and noted growing responses for EASI-75, 90, vIGA and itch as time went on; this also featured as much as a fivefold rise in EASI-100 rates, meaning complete skin clearance, a response level patients seldom reach. One key distinguishing discovery from REZOLVE-AD was the improvement in patient-reported comorbid asthma. Roughly 25% of patients who have moderate to severe atopic dermatitis also suffer from asthma, and the majority of approved therapies fail to tackle this comorbidity. At week 16, compared with placebo, REZPEG delivered statistically significant gains in the asthma control questionnaire, or ACQ-5, scores, including among patients whose asthma was uncontrolled at baseline. Apart from Dupixent, no other approved agent or late-stage candidate has shown this; we're adding ACQ-5 as a secondary endpoint in the Phase III program, aiming to potentially get this into the label. In Q1 of 2027, we anticipate reporting 52-week off-treatment data from REZOLVE-AD. Those data will let us evaluate REZPEG's remittent potential past 52 weeks, and we're eager for them; we've finished the end of Phase II meeting with the FDA and the scientific advice process with the EMA, and we'll launch the first trial in the global Phase III program by July of this year. Our planned registrational program, known as ZENITH-AD, should encompass 3 trials altogether, 2 global monotherapy studies each with 510 biologic-naive patients 12 years and older, plus a separate study of 510 treatment-experienced patients 12 years and older. In the case of the 2 key trials involving patients who have not previously received biologics, randomization will assign participants in a 2:1 ratio to either 24 micrograms per kilogram administered once every 2 weeks or placebo across a 24-week induction stage, which is then followed by a maintenance span of 28 weeks, with monthly and quarterly dosing schedules assessed up through week 52. The general framework is meant to align with earlier registrational trials that backed approval of biologics for atopic dermatitis. Enrollment for the initial 2 trials in biologic naive individuals opens first, commencing in July of this year, while the third trial, in those with prior biologic experience, will start a few months afterward. Findings from our market research back the use of REZPEG as both a first-line and second-line biologic treatment, and we have structured the program to reflect this within the potential label. Beyond these 3 pivotal Phase III trials, the program will encompass additional studies intended to support registration. Among them will be a 200-patient open-label trial in adolescents plus a long-term extension trial. Furthermore, we intend to introduce REZPEG alongside an auto-injector, and the BLA filing will contain a PK bridging study to back that. The agency has not mandated a vaccine study, which was required in certain earlier Phase III programs for this indication. The Phase III trials are built to support registration in both the U.S. and EU, using an IGA-related primary endpoint for the U.S. and an EASI-75 coprimary endpoint for European approval. A set of multiplicity protected endpoints covering itch and other key patient reported outcome measures, including sleep, quality of life and asthma control, are incorporated into the trials as well. We anticipate a country distribution comparable to Phase II, with the addition of certain other countries in Asia to reflect the global footprint. As Howard mentioned, we expect the initial data readout from the Phase III program in the middle of 2028. Turning next to alopecia areata. We recently shared the 52-week top line results from the blinded 16-week treatment extension of our Phase IIb REZOLVE-AA study. To recap, our Phase IIb REZOLVE-AA trial enrolled 92 adult patients with severe to very severe alopecia areata. Participants were given subcutaneous REZPEG at 24 micrograms per kilogram every 2 weeks, 18 micrograms per kilogram every 2 weeks or placebo. The primary and key secondary endpoints were evaluated at the conclusion of the 36-week induction period, which we reported last December. Those data provided proof of concept in alopecia areata and demonstrated that REZPEG achieved the target product profile of standard of care low-dose JAK inhibitor. The extension phase was purpose-built to assess whether continuing REZPEG treatment past week 36 could push more patients to reach a SALT Score 20 response. SALT Score 20 means a patient attains 80% or more scalp hair coverage, the established registrational endpoint in alopecia areata. This mattered greatly in deciding whether our Phase III program in alopecia areata ought to use a 36-week or 52-week primary endpoint treatment period. April's data demonstrated that ongoing REZPEG treatment produced meaningful new responses among patients who hadn't reached a SALT Score of 20 by week 36. Among the 31 patients in the 18 and 24 microgram per kilogram dose arms who entered the blinded treatment extension, 29% and 31%, respectively, achieved new SALT Score 20 responses between weeks 36 and 52, while placebo produced no new responses. Looking at other SALT measurements, growing shares of patients hit clinically meaningful hair growth thresholds; and notably, REZPEG met the target product profile with 52 weeks of twice monthly dosing. Worth noting, nearly all patients — 94% — who entered the blinded 16-week extension period completed treatment through week 52. That shows when patients grasp REZPEG's promise to grow hair, they'll stick with twice monthly treatment. As Howard said, we plan to hold an end of Phase II meeting with the FDA this quarter, with EMA scientific advice coming later this year, to align on the global registrational path forward in alopecia areata. Our ongoing Phase IIb REZOLVE-AA study also includes a 24-week off-treatment observation period for all patients. We expect this data in Q4 2026; it will give us a chance to understand what dosing regimens of REZPEG to use beyond 52 weeks in alopecia areata patients and whether a less frequent dosing regimen should be included in the registrational program.
Jonathan Zalevsky
executiveWe think the 52-week results for REZPEG put it in a strong spot to tackle a number of important unmet needs. Number one, its long-term safety picture stands apart, which includes being appropriate for chronic administration without the safety and monitoring constraints that come with the JAK inhibitor class. Number two, a dosing schedule of twice a month allows for improved potential compliance. And number three, there's the chance for efficacy that becomes more durable and continues to deepen as time goes on. Past our 2 lead indications, we're going after the wider potential that the Treg mechanism offers. When it comes to type 1 diabetes, the Phase II trial of REZPEG that is underway has TrialNet as its sponsor and funder, and it is assessing REZPEG in patients who have new onset Stage 3 type 1 diabetes. As a reminder, TrialNet is the very same consortium that conducted the foundational studies for Teplizumab, which is the sole approved therapy in this setting, and they contribute expertise along with a deep dedication to finding better options for patients given this diagnosis. Within the trial, patients get randomized 2:1 to either REZPEG or placebo, and they are treated every 2 weeks for 6 months across 3 sequential age cohorts, beginning with adults 18 to 45 and then stepping down to patients as young as 12 and afterward 8 years of age. The primary endpoint is the change in C-peptide levels following a mixed meal tolerance test at 12 months of treatment. We anticipate initial data from this trial in 2027. Because of the difficulties with administering Teplizumab and its safety, REZPEG might be well positioned for new onset type 1 diabetes. We also intend to launch a proof-of-concept study in at least one new indication during the second half of 2026, with initial data anticipated in 2027. We're examining the disease settings in which a T regulatory mechanism has shown clinical activity, and this will help guide our choice about which indication to prioritize, with the aim of achieving another data catalyst for REZPEG in 2027. Now shifting to our earlier pipeline programs, NKTR-0165 and NKTR-0166. NKTR-0165 is our TNFR2 agonist antibody, a molecule that is extremely specific for signaling through TNFR2 on Tregs in order to boost their capacity to regulate the immune system. We think this mechanism holds potential across a variety of indications, among them MS, ulcerative colitis and vitiligo. In Q1, we announced an academic research collaboration with Dr. Stephen Hauser at UCSF to investigate the role of TNFR2 agonism in neurodegeneration, neuroprotection and cell repair, with a focus on patient-derived B-cell models of MS; we look forward to collaborating with Dr. Hauser to help shape the future development of this program. We anticipate presenting preclinical data from NKTR-0165 at a scientific conference in the second half of this year. Drawing on what we learned from NKTR-0165, we have designed NKTR-0166, a bispecific molecule that pairs a TNFR2 agonist epitope with an antagonist epitope that was previously validated in rheumatology. This dual mechanism provides NKTR-0166 with the potential to modify disease pathogenesis across multiple autoimmune settings, and we intend to make IND submissions for at least one of these programs in 2027. Having said that, I'll now hand things over to Sandy, who will walk us through the financial results for the first quarter of 2026.
Sandra Gardiner
executiveThanks, JZ, and good afternoon to all of you. During this call, I'll walk through the financial results for our first quarter of 2026 and give you an update on cash guidance. We closed the first quarter of 2026 holding $731.6 million in cash and investments, and our balance sheet carries no debt. During the first quarter, we finished an underwritten public offering plus sales through our existing ATM facility, which brought in roughly $525 million in net cash proceeds. That figure leaves out another $351 million in net proceeds from the financing we completed in April. As Howard said before, our cash balance right now is above $1 billion, and we anticipate finishing 2026 with somewhere around $800 million to $825 million in cash and investments. Let me move on to the income statement. Noncash royalty revenue for the first quarter of 2026 came to $10.9 million. For all of 2026, revenue is still projected to reach $40 million to $45 million. R&D expenses for the first quarter of 2026 were $35.7 million, and we continue to expect full year R&D expense to fall somewhere between $200 million and $250 million, which includes roughly $5 million to $10 million of noncash depreciation and stock-based compensation expense. As we talked about on our March call, planning and budgeting work for the REZPEG Phase III program is still being finalized. That said, we do expect R&D expense to rise each quarter in 2026 as those Phase III clinical studies get underway. Our G&A expenses came in at $13.4 million for the first quarter; for the full year of 2026, we still expect G&A expenses to land between $60 million and $65 million, including about $5 million of noncash depreciation and stock-based compensation expense. Noncash interest expense for the first quarter was $7.9 million, and we expect it to stay at a comparable level across the remaining 3 quarters, totaling roughly $30 million to $35 million in 2026. Our net loss for the first quarter was $44.9 million, or $1.82 basic and diluted net loss per share. And as I mentioned earlier, we now expect to finish 2026 with between $800 million and $825 million in cash and investments. I'll hand it over to the operator now for Q&A.
Dominic Lorenzi
analystHey, it's Dominic, filling in for Yasmeen Rahimi. Nice work on the quarter, and thanks for all the updates. We're pumped that you'll be launching the Phase III AD program before long. Can you run through which rate-limiting steps are still ahead for those — I believe there are 2 trials beginning in the near future? And then could you share some of the finer points? I recall you mentioning that certain sites will be comparable to the Phase IIb. So how much site overlap should we expect? Any specifics you can give about the CRO selection? Anything along those lines would really help.
Mary Tagliaferri
executiveDominic, Mary here. Thanks for asking; we're equally thrilled to push ahead with the Phase III study. At this point we're activating sites, and the final protocol has been written. Regarding sites, keep in mind that in REZOLVE-AD Phase II, 17% of the patients we enrolled were from the United States and 28% from North America, while 67% of the patients came from Europe and 5% from Australia; under the Phase III program, our footprint is going to be bigger, especially in the APAC region, or the Asian Pacific region; broadly speaking, we expect to enroll about 15% to 25% of patients from North America, with a proportion of patients specifically from the United States similar to what we saw in our Phase IIb trial, and then approximately 40% to 55% of patients will come from Europe and roughly 20% to 30% from APAC. A number of clinical sites that took part in our Phase IIb program will also take part in the Phase III. For the Phase IIb trial, roughly 130 sites were activated, and for each one of the Phase III studies, we'll activate roughly 150 sites. Thanks for your question.
Julian Harrison
analystCongrats on everything you've achieved so far; regarding your Phase III trial in atopic dermatitis, could you elaborate on why you chose a standalone study for patients with prior biologic exposure instead of perhaps enrolling a mix of naive and experienced individuals across 2 bigger trials?
Mary Tagliaferri
executiveSure. Julian, I appreciate you asking that. As you know, the cytokine blocking agents that preceded ours only enrolled patients who had never received a biologic. We really believe it matters to be able to put the results from the REZPEG study on EASI-75, the IGA and other secondary endpoints side by side with those cytokine blocking agents, and that's why we want a population consisting solely of naive patients. As for the experienced group, our expectation is that efficacy will look comparable there, and that is indeed what the lebrikizumab trial showed when it looked at patients who'd already been on Dupixent. The EASI-75 and the IGA score came out similar to lebrikizumab's results in patients who were naive. That said, we haven't yet examined those with prior biologic exposure among the JAK inhibitor experienced patients. Also, certain clinical sites may have more patients who are biologic experienced, so locating the footprint and getting those individuals enrolled, then activating those sites for the experienced study, should be simpler for us. So from an operational standpoint, we see benefits to taking this approach. And once more, being able to make direct comparisons with Dupixent, lebrikizumab and trilkizumab, which only enrolled naive patients, strikes us as advantageous. So I appreciate the question.
Jay Olson
analystLet me also say congratulations on everything that's been achieved, including the near-term launch of ZENITH-AD. One thing we wanted to ask about is alopecia areata. Could you share where your thinking stands regarding the Phase III trial design for REZPEG in AA, particularly on the enrollment criteria — the age of patients and baseline SALT Score — and then whether you believe one Phase III study would be enough?
Mary Tagliaferri
executiveThanks for that question, Jay. Our end of Phase II meeting with the FDA is happening this quarter. So once that regulatory meeting takes place, we'll be able to share more. With that said, the design for the Phase III study is set at 52 weeks. The comparison we'll evaluate is REZPEG 24 micrograms per kilogram against placebo. Our belief is that a single study, enrolling approximately 600 patients, ought to be accepted by the FDA. Our basis for that belief: Pfizer ran 1 Phase III study for Litfulo, their JAK inhibitor, and 1 single Phase III study was accepted by the FDA. So we've asked the FDA to confirm that this precedent would apply to our program as well. On age, enrollment would be for patients 12 years and older. As for baseline SALT Score, the patients we enroll will have severe and very severe alopecia areata, meaning a SALT Score of 50 or above. A question many people have raised with us is whether REZPEG could be developed for moderate alopecia areata patients, and our view is that yes, the answer is. That said, it would follow an approval in the severe and very severe population. And naturally, given the black box warnings Howard mentioned and how difficult it is to manage patients on JAK inhibitors, those drugs aren't appropriate for that patient population. Still, in that population we see a huge opportunity for REZPEG as well.
Cha Cha Yang
analystCha Cha here, stepping in for Roger Song. My first question concerns the pipeline program you mentioned earlier, particularly in T1D. Could you share additional details regarding the TrialNet collaboration—what it involves, and specifically which rights Nektar holds concerning data and future development rights? My second question, tied to that, is whether you can provide more information on the baseline characteristics of the T1D study and how those might stack up against the PROTECT study?
Jonathan Zalevsky
executiveAbsolutely. Regarding the TrialNet collaboration—TrialNet is affiliated with the NIH and the NIDDK, and along with providing funding, the TrialNet consortium also carries out the study itself. Consequently, we jointly develop the study protocol design. It draws on the full breadth of their expertise, which includes the extensive dataset they possess regarding shifts in C-peptide levels among patients who are newly diagnosed—essentially this exact patient population. Additionally, we collaborate closely with the lead investigators. In fact, during our call announcing the collaboration's launch, the 2 lead PIs were on that call alongside us to present the study and the rationale for REZPEG in this indication. So we will be working alongside them, though they hold responsibility for truly propelling the study's execution. This patient population is extremely typical for studies of this kind. That means patients who are within 100 days of their initial type 1 diabetes diagnosis. In other words, these individuals have only recently experienced their first clinical episode of the disease, and they get enrolled in the study within 100 days. So it's a highly typical patient population for these sorts of new onset Stage III type 1 studies. As for the rights, Nektar retains the rights to REZPEG and to future development in type 1 diabetes that would follow from this, should this study prove possible.
Samantha Semenkow
analystI've got a single question about the off-treatment datasets we anticipate seeing for atopic dermatitis as well as alopecia areata. What should our expectations be regarding what favorable results would look like in those readouts? Is there, say, a threshold for simple maintenance, or a SALT Score maintenance level you'd want to observe from either one, or any other measures you're monitoring closely?
Mary Tagliaferri
executiveSam, I believe I'll take alopecia areata first. Those 27 patients are still being dosed by us for another 16 weeks, and we recently disclosed that information. As you observed, 8 additional patients newly reached a SALT Score at or below 20. What we're really asking ourselves is which maintenance dosing approach would work best for these individuals who've gotten a SALT Score under 20 or who've had 80% hair regrowth. We worked that out within our atopic dermatitis program — the optimal maintenance dosing following a 16- or 24-week induction phase ought to be 1 month and 3 months. Regarding alopecia areata, following 52 weeks of treatment, what the maintenance dosing ought to be remains unknown to us. Therefore, for the off-treatment data coming at the end of this year, it will be extremely informative for us in figuring out how patients in the alopecia areata program should keep being dosed beyond 52 weeks of treatment with 24 micrograms per kilogram every 2 weeks. As for the REZOLVE-AD study data, you're completely correct. We'll keep tracking how long those responses last in patients who reached an EASI-75 and EASI-90 and IGA 0 and 1, and we'll keep examining how durable those responses are. With Q monthly dosing and Q 3 months dosing, as we observed, durability was exceptional, and we additionally observed responses deepening. With the off-treatment period now, we can figure out whether patients can hold onto those EASI-100 responses — the 30% of patients who got there — plus the IGA 0 and 1 responses. And keep in mind, roughly 60% of patients who had an EASI-75 or vIGA when rerandomization occurred were achieving an IGA of 0 and 1. So watching how durably the EASI-75, the EASI-100 and vIGA-01 are maintained is something we're quite eager to see. Once more, I think this will be extremely informative for grasping the dosing frequency for these patients following 52 weeks of treatment. So you're completely correct. The standard endpoints we rely on for clinical trials will likewise be the endpoints we examine during the off-treatment period. Thanks for the question.
Marc Frahm
analystCongratulations on everything you've accomplished with the trial designs. Perhaps focusing on that study involving bio-experienced patients in atopic dermatitis — could you describe exactly how bio-experience is being characterized for this? Is prior therapy failure a strict requirement, or is discontinuation for any reason acceptable? What's the minimum time they must be off treatment, and similar details? Also, does this encompass patients who've had JAK exposure, or is it limited to the IL-413 pathway?
Mary Tagliaferri
executiveMarc, appreciate the question. Every candidate must need systemic therapy. That means a documented history of atopic dermatitis spanning no less than 12 months, plus an inadequate response to topicals. Beyond that, each patient must also have received either a biologic or a JAK inhibitor. So enrollment will include individuals who've taken JAK inhibitors too. Regarding washouts, biologic-treated patients need to have been off therapy for either 12 weeks or 5 half-lives, whichever is greater. For JAK inhibitors, a 4-week washout applies. Eligibility requirements for moderate to severe atopic dermatitis are nearly identical across both studies — naturally, patients need an EASI score of at least 16, body surface area involvement of 10% or greater, and an IGA entry of 3 or 4.
Marc Frahm
analystAll right, that's really useful. In your view, do all 3 trials have to succeed for approval, or would 2 of the 3 be sufficient?
Mary Tagliaferri
executiveYeah. That's a great question about the regulatory path; as we unblind the data and speak with our regulatory advisers, I do believe that demonstrating efficacy in 2 well-controlled randomized trials would be enough for regulatory approval. But once more, we'll need to have those discussions with the FDA when we submit our BLA.
Mayank Mamtani
analystCongratulations on the advancement. Regarding what was said earlier about the AD off-therapy durability data, I'm just wondering, how do you anticipate an endpoint such as EASI-100 changing as time goes on? Then, about the earlier stage pipeline, the program specific to 0165, JZ, I was just wondering how you plan to develop that, perhaps in relation to 0165? And maybe just give us a reminder of the key milestones to keep an eye on for those 2 programs?
Jonathan Zalevsky
executiveMayank, I'll take the last question first. So regarding 0166, as we said, it's a bispecific, correct? It has a TNFR2 agonist on 1 arm, and on the other arm a validated target for rheumatology indications; so our indications are certainly within the rheumatology setting; and then we have the chance to basically have multiple mechanisms, right, that we advance on the cell as well as adding a TNFR2 second component for a potentially differentiating novel approach to treating rheumatology diseases. As for the main milestones we have across that program, we have IND-enabling studies around 0165, and then the 0166 program is a little bit further behind, though it's also going through those same IND-enabling studies as well. And for the other question, I'll turn it over to you, Mary.
Mary Tagliaferri
executiveRight, so as everyone is aware, we published findings from our Phase Ib trial in Nature Communications back in 2024. What we demonstrated was that patients received REZPEG at the maximum dose of 24 micrograms per kilogram, and following 12 weeks of treatment, those same patients stayed off therapy for 9 months altogether. We observed that these individuals could hold onto their EASI-75, and the durability was quite striking, as you're able to see in that publication. So should we reproduce what we saw in the early Phase I, we'd expect durability lasting potentially 9 to 12 months with no therapy. Again, the aim here, I believe, is identifying a treatment regimen that stands apart significantly from what's currently on the market. As you're aware, with Dupixent, patients must receive an injection every 2 weeks with no end point. We genuinely think that if we can achieve a REZPEG dosing schedule that is monthly or quarterly, much like SKYRIZI 4 times a year, that would represent an enormous benefit for patients and a real shift in this therapeutic area. With luck, the data will additionally demonstrate durability while off treatment; and so, should patients remain without dosing beyond 3 months, particularly if they reach EASI-100, meaning complete clearance of disease, and possess that degree of durability, it would be a tremendous advantage for patients. I believe all of us are keen to see the data and to learn how long patients are able to sustain their IGA 0 or their EASI-75, EASI-90, and EASI-100. So we're very much anticipating having that data during the first quarter of next year. Thanks for asking that question.
Arthur He
analystCongratulations on the advancement; I have 2 brief questions regarding the alopecia areata program. First, might you remind us why the 24-week treatment duration was selected initially, rather than something longer? Additionally, for the Phase III trial, are you considering enrolling patients who have prior JAK inhibitor exposure or are refractory into the Phase III alopecia areata study?
Mary Tagliaferri
executiveWe selected the 24-week off-treatment duration since, as you might be aware with JAK inhibitors, hair loss occurs fairly rapidly in patients, so we believed that was enough time to possibly observe a distinction between JAK inhibitors and REZPEG. Regarding the Phase III, we will enroll patients who are naive to JAK inhibitors. That said, there are several alternative approaches to assess REZPEG in a population with prior JAK inhibitor experience. We think that for this specific indication, REZPEG might serve as a first-line treatment. For those who could hear our presentation on the 52-week alopecia areata data, every one of our KOLs stated that the majority of patients, and actually Jonathan Silverberg mentioned 90% of his patients, would choose REZPEG as initial therapy. Thus, we do and we are placing REZPEG as a first-line option for alopecia areata. We also think the drug will work effectively in patients who have previously taken a JAK inhibitor, and we will identify a different route to investigate REZPEG and assess REZPEG in that group too. So thank you for the question, Arthur.
Andy Hsieh
analystI just want to add to what Jay asked earlier. Mary, you brought up the need to run a Phase III study in alopecia and secure a label before running a study in a moderate population. So I'm wondering, first, must you return to a Phase II, or is it possible to launch a Phase III right after? And second, I really want to grasp the FDA's resistance. Is it that they aren't at ease with the safety database, particularly given that you now have hundreds of patients in it? So I'm just wondering why there's this kind of regulatory resistance when it comes to a moderate population.
Mary Tagliaferri
executiveWe do need to talk with the agency regarding the moderate population. That said, after discussions with members of our steering committee, the placebo effect in alopecia areata among patients whose disease is severe or very severe is quite low. With SALT 20, it's in the single digits, ranging from 2% to 5%. So conducting a clinical trial in which the placebo effect on your primary efficacy endpoint is low, and studying the same population as our Phase IIb AA study, gives us a strong probability of technical success for our registrational program. That said, in the moderate patient population, according to our KOLs and our steering committee, the placebo effect might be greater among patients whose SALT Score is, say, actually below 50, meaning within the 30 to 50 range. So we think the best route forward is to rely on the clear regulatory precedent where there's a clear endpoint for the patient population at a SALT 50 or above. And we will discuss the moderate patient population with the FDA. We haven't yet received feedback via our end of Phase II, nor on the moderate population. So no pushback has come our way. We simply haven't had that conversation yet, Andy.
Jessica Fye
analystThis is for Joseph, on behalf of Jess. It looks like a lot of the plan for the Phase III in alopecia is already in place; so I was just wondering if you could — what are the things you can hammer out, that you want to hammer out, with the FDA at the end of Phase II meeting?
Mary Tagliaferri
executiveYes. Of course, a lot has come up regarding whether you can conduct 1 Phase III clinical trial as opposed to 2, and again, there is precedent for 1 Phase III clinical trial for this indication. Like we said, Pfizer managed to get their JAK inhibitor approved with 1 Phase III. So I would say that is probably the most important question and answer we want from the FDA following our end of Phase II meeting. Also, we have submitted our study design, and we want to confirm that the FDA is in agreement with the powering of our trial and the eligibility criteria. And I believe the third, and also important, point is the totality of our safety data. As Andy Hsieh just mentioned, we do have a very large safety database, with over 1,000 patients dosed in an inflammatory skin disease. And so we also want alignment with the agency regarding the safety database for alopecia areata when we file our BLA; so those are 3 of the most important topics on which we want clarity and alignment with the agency. Thanks for the question.
Howard Robin
executiveAlright, as we wrap up today's call, I'd like to note that Sandy, who is currently serving as our interim CFO, is set to retire on May 15. In her capacity as interim Chief Financial Officer, Sandy has been absolutely vital in backing Nektar throughout the past 3 years, and her efforts mean a great deal to us — she will certainly be missed. To keep things running smoothly, we're adding another partner from FLG Partners, Linda Rubinstein, who is stepping into Sandy's position as interim CFO. Linda brings 35 years of experience to the table and has held interim or permanent CFO roles, heading up finance and financial reporting, at multiple biotech firms such as Solexa, Five Prime, True North and, most recently, Adverum. She began her career in M&A banking; and every one of us wishes Sandy all the best in her retirement. I'd like to express my thanks to all of you for joining us today and for your ongoing support; we truly appreciate it. I also want to give thanks to our employees, who have labored tirelessly to push our research forward in the pursuit of novel treatment options for patients, and collectively, we've turned our scientific hypothesis into real and potentially meaningful therapeutic options. We're eager to kick off our Phase III studies in atopic dermatitis in the months ahead and to move alopecia areata into Phase III as well. On top of that, we'll be investigating other REZPEG potential in T-cell-mediated diseases. So thank you so much for being with us today, and stay tuned.
Operator
operatorAppreciate it. That brings us to the end of the call for today. We're grateful that all of you joined us. You're free to hang up now. Wishing each of you a great rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.